LPCN / Lipocine Inc. - SEC Filings, Annual Report, Proxy Statement

EX-99.1

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 5, 2025 LIPOCINE INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 5, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Exhibit 99.1 Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference SALT LAKE CITY, UT, September 5, 2025/PR NEWSWIRE/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that Company Management will present and meet with investors at the H.C.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 5, 2025 LIPOCINE INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 5, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 26, 2025 LIPOCINE INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 26, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Exhibit 99.1 Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025 SALT LAKE CITY, UT, August 26, 2025/PR NEWSWIRE/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that two abstracts related to LPCN 2101 have been accepted for poster present

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Exhibit 99.1 Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 SALT LAKE CITY, August 5, 2025 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced financial results for the second quarter ended June 30, 2025 and provided a corporate update

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36357 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2025 LIPOCINE INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (I

LPCN 1154 for Depression R&D Event, July 9th 2025

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 9, 2025 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 9, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 2, 2025 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 2, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Corporate Presentation

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 26, 2025 LIPOCINE INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 26, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression Phase 3 Top Line Results Expected Q2 2026

Exhibit 99.1 Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression Phase 3 Top Line Results Expected Q2 2026 SALT LAKE CITY, June 26, 2025 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that the first patient has

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIOTM) as a Treatment for Postpartum Depression on July 9, 2025

Exhibit 99.1 Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIOTM) as a Treatment for Postpartum Depression on July 9, 2025 SALT LAKE CITY, June 23, 2025 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that it will host a virtual research

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2025 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

Exhibit 99.1 Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada ● New Drug Submission filed by Lipocine’s licensing partner Verity Pharma ● Over 700,000 total prescriptions written annually for testosterone replacement therapy (TRT) in Canada, representing large commercial opportunity SALT LAKE CITY, June 9, 2025 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 4, 2025 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 4, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Lipocine Inc.

Exhibit 3.4 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LIPOCINE INC. Lipocine Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of this corporation is Lipocine Inc. and the date on which the Amended and Restated Certificate of Incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 22, 2025 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 22, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Lipocine’s LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

Exhibit 99.1 Lipocine’s LPCN 1148 Highlighted in the June 2025 Edition of Hepatology SALT LAKE CITY, May 22, 2025 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its development candidate LPCN 1148 for men with cirrhosis is featured in the “Hepatology Highlights”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 14, 2025 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 14, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Lipocine to Present at A.G.P.’s Annual Healthcare Company Showcase

Exhibit 99.1 Lipocine to Present at A.G.P.’s Annual Healthcare Company Showcase SALT LAKE CITY, May 14, 2025 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that it will present at A.G.P.’s Annual Healthcare Company Showcase being held virtually on Wednesday, May 21,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2025 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Corporate Presentation

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2025 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36357 LIPOCINE INC. (Exact

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

Exhibit 99.1 Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 SALT LAKE CITY, May 8, 2025 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the first quarter ended March 31, 2025 and provided a corporate update. Neuro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2025 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

Exhibit 99.1 Lipocine Announces License and Supply Agreement for TLANDO® in Brazil SALT LAKE CITY, May 6, 2025 / PRNewswire / — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that it has entered into license and supply agreement with Aché Laboratórios Farmacêuitcos S.A (Aché

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

Corporate Presentation

Exhibit 99.1

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 3, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 26, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (I

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Exhibit 99.1 Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 ● 48 hour at-home dosing ● Patient dosing expected in Q2/2025 SALT LAKE CITY, March 26, 2025 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced the initiation of a Phase 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36357 LIPOCINE INC. (Exact name

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Exhibit 99.1 Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 SALT LAKE CITY, March 13, 2025 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the year ended December 31, 2024, and provided a corporate update. Oral Bre

Lipocine Inc. Insider Trading Policy

Exhibit 19 LIPOCINE INC. INSIDER TRADING POLICY NOVEMBER 17, 2023 BACKGROUND The Board of Directors of Lipocine Inc. (“Lipocine” or the “Company”) has adopted this Insider Trading Policy (the “Policy”) for our directors, officers, employees, consultants and their respective affiliates (including entities or trusts that own Company securities and are controlled by such persons) (“Covered Persons”),

SUBSIDIARIES

EXHIBIT 21.1 SUBSIDIARIES Lipocine Operating Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2025 LIPOCINE INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 12, 2025 LIPOCINE INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 12, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (I

Lipocine Announces FDA Labeling Changes for Testosterone Products

Exhibit 99.1 Lipocine Announces FDA Labeling Changes for Testosterone Products SALT LAKE CITY, March 12, 2025 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and Drug Administration (FDA) has recently informed sponsors of approved testosterone produ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 11, 2025 LIPOCINE INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 11, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Corporate Presentation

Exhibit 99.1

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Exhibit 99.1 Lipocine Receives Updated Regulatory Guidance on LPCN 1154 SALT LAKE CITY, Feb. 6, 2025 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced receipt of revised regulatory guidance for LPCN 1154 which the Company is developing for postpartum depression (PPD) tr

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 6, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Corporate Presentation

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2025 LIPOCINE INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2025 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Exhibit 99.1 FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis SALT LAKE CITY, Dec. 17, 2024 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that the U.S. Food and Drug Administration (“F

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 17, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Corporate Presentation

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 13, 2024 LIPOCINE INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 13, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 18, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor’s Cut Session

Exhibit 99.1 Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor’s Cut Session SALT LAKE CITY, Nov. 18, 2024 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the publication and discussion of a manuscript “Oral LPCN 11

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Exhibit 99.1 Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 SALT LAKE CITY, Nov. 7, 2024 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the third quarter and nine months ended September 30, 2024 and provided

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 7, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36357 LIPOCINE INC. (Ex

Poster presentation entitled “Oral LPCN 2401 Reduces Fat Mass and Increases Lean Mass in Men with Obesity”

Exhibit 99.1

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 5, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 28, 2024 LIPOCINE INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 28, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Exhibit 99.1 Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea SALT LAKE CITY October 31, 2024 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced a license, development and supply agreement with to SPC Korea http

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 22, 2024 LIPOCINE INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 22, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Third Amended & Restated Rights Agreement, dated October 22, 2024.

Exhibit 4.1 LIPOCINE INC. and EQUINITI TRUST COMPANY, LLC, as Rights Agent THIRD AMENDED & RESTATED RIGHTS AGREEMENT Dated as of October 22, 2024 TABLE OF CONTENTS Page Section 1. Certain Definitions 2 Section 2. Appointment of Rights Agent 8 Section 3. Issue of Right Certificates. 9 Section 4. Form of Right Certificates 10 Section 5. Countersignature and Registration. 11 Section 6. Transfer, Spli

Certificate of Amendment to Certificate of Designation of Series A Junior Participating Preferred Stock.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF DESIGNATION OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF LIPOCINE INC. (Pursuant to Section 151 of the General Corporation Law of the State of Delaware) Lipocine Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, in accordance with the provisions of Section 103 ther

KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management Presentation

Exhibit 99.1

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 16, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Exhibit 99.1 Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results ● Quantitative Electroencephalogram (qEEG) in healthy subjects administered single doses of oral brexanolone, a neuroactive steroid (NAS), confirmed GABAA modulation ● Rapid and durable CNS target engagement confirms effective oral delivery of bioidentical brexanolone ● Promising results support continued developmen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 10, 2024 LIPOCINE INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 10, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

H.C. Wainwright 8th Annual MASH Investor Conference Presentation

Exhibit 99.1

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Exhibit 99.1 Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries SALT LAKE CITY, Oct. 8, 2024- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced an exclusive supply and distribution

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 7, 2024 LIPOCINE INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 7, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 8, 2024 LIPOCINE INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 8, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Exhibit 99.1 Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 SALT LAKE CITY, October 2, 2024 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that it will host a virtual key opinion le

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 2, 2024 LIPOCINE INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 2, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 30, 2024 LIPOCINE INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 30, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Exhibit 99.1 Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference SALT LAKE CITY, September 30, 2024 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that it will present and meet with investors at the H.C. Wainwright 8th Annual MASH Investor Conf

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek® Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with at least one weight-related comorbidity

Exhibit 99.1 Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek® Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with at least one weight-related comorbidity SALT LAKE CITY September 5, 2024 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics throug

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 5, 2024 LIPOCINE INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 5, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 27, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction (IRS Employer of in

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

EX-99.1 2 ex99-1.htm Exhibit 99.1 Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference SALT LAKE CITY, August 27, 2024— Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that Dr. Mahesh V. Patel, President and Chief Executive Officer, will prese

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Quarterly Period ended June 30, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36357 LIPOCINE INC. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2024 LIPOCINE INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (I

LIPOCINE INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets

Exhibit 99.1 Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024 SALT LAKE CITY, August 08, 2024 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the second quarter ended June 30, 2024 and provided a corporate update. L

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 5, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (I

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 25, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

Exhibit 99.2 Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 SALT LAKE CITY, June 10, 2024 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 results on LPCN 1148 in cirrhosis were featured in a late breaking oral presentation at the European Association for the Study of Liver (EASL) Congress on Sa

Presentation entitled “Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy (HE) in patients with cirrhosis: a 52-week phase 2 randomized clinical trial”

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 8, 2024 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 8, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 5, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 18, 2024 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 18, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Fifth Amended and Restated 2014 Stock and Incentive Plan

Exhibit 10.1 FIFTH AMENDED AND RESTATED LIPOCINE INC. 2014 STOCK AND INCENTIVE PLAN Section 1. Purpose The purpose of the Plan is to promote the interests of the Company and its stockholders by aiding the Company in attracting and retaining employees, officers, consultants, advisors and non-employee Directors capable of assuring the future success of the Company, to offer such persons incentives t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Quarterly Period ended March 31, 2024 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to. Commission File Number: 001-36357 LIPOCINE INC. (Exact name

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

Exhibit 99.1 Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 SALT LAKE CITY, May 9, 2024 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. LPCN 1154 for Postpartum Depression ● In May 2024, dosing of subjects was completed in the pivotal pharmacok

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

Exhibit 99.1 Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 SALT LAKE CITY, May 8, 2024 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver (“EASL”) Con

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2024 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 1, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 Pivotal study design aligned with FDA on streamlined pathway to NDA submission goal in 2024 Topline results anticipated late in 2Q 2024

Exhibit 99.1 Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 Pivotal study design aligned with FDA on streamlined pathway to NDA submission goal in 2024 Topline results anticipated late in 2Q 2024 SALT LAKE CITY, May 1, 2024 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that dosing of subjects has be

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 29, 2024 LIPOCINE INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 29, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (I

Corporate Presentation

Exhibit 99.1

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2024 LIPOCINE INC.

Sales Agreement dated April 26, 2024 by and between Lipocine Inc., and A.G.P./Alliance Global Partners

Exhibit 1.1 LIPOCINE INC. COMMON STOCK SALES AGREEMENT April 26, 2024 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Lipocine Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners, as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term

Up to $10,616,169 of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-275716 Prospectus Supplement (To Prospectus Dated April 25, 2024) Up to $10,616,169 of Common Stock This prospectus supplement relates to the offer and sale, from time to time, of shares of our common stock having an aggregate gross sales price of up to $10,616,169, to or through Alliance Global Partners (“A.G.P.”), acting as our sales agent, i

Lipocine Inc. 675 Arapeen Drive, Suite 202, Salt Lake City, Utah

Lipocine Inc. 675 Arapeen Drive, Suite 202, Salt Lake City, Utah April 24, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Doris Stacey Gama Re: Lipocine Inc. – Registration Statement on Form S-3 (File No. 333-275716) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 19

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

As filed with the Securities and Exchange Commission on April 23, 2024

As filed with the Securities and Exchange Commission on April 23, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Lipocine, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (3) Fee Rate Amount of Registration Fee Carr

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 11, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (I

“ LPCN 2401 for Obesity Management, Clinical Study Results”

Exhibit 99.2

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Exhibit 99.1 Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity ● LPCN 2401 treatment resulted in statistically significant body composition improvement in men ● Increased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7% ● Reduced android fat (AF) by 4.1% and increased bone mineral content (BMC) by 2.8% ● Well-tolerated,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 28, 2024 LIPOCINE INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 28, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (I

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Exhibit 99.1 Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis ● Met primary and Hepatic Encephalopathy (HE) endpoints in Phase 2 study ○ Increase in Skeletal Muscle Index (SMI) observed at Week 24 was maintained through 52 weeks ○ Participants on placebo increased SMI when switched to LPCN 1148 ○ Fewer Overt Hepatic Encephalopathy (OHE) events and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 25, 2024 LIPOCINE INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 25, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (I

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 Company anticipates topline results from this crossover pivotal study late in the second quarter of 2024

Exhibit 99.1 Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 Company anticipates topline results from this crossover pivotal study late in the second quarter of 2024 SALT LAKE CITY, March 25, 2024 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform, today annou

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Exhibit 99.1 Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 SALT LAKE CITY, March 7, 2024 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (“CNS”) disorders, today announced financial results for the year ended December 31, 2023 and provided a corporate update. Neuroactive Steroids ● Lipocine announced positive t

Lipocine Inc. Clawback Policy

Exhibit 97 LIPOCINE INC. INCENTIVE COMPENSATION RECOVERY POLICY 1. Introduction. The Board of Directors of Lipocine Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s compensation philosophy. The Board has therefore adopted this policy, whi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36357 LIPOCINE INC. (Exact name

Corporate Presentation

Exhibit 99.1

SUBSIDIARIES

EXHIBIT 21.1 SUBSIDIARIES Lipocine Operating Inc.

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 7, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 7, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

License Agreement dated January 12, 2024 by and among Lipocine, Inc., Gordon Silver Limited, and Verity Pharmaceuticals

Exhibit 10.28 LICENSE AGREEMENT This License Agreement (this “Agreement”) is made and entered into on January 12, 2024 (the “Signing Date”) and is effective as of February 1, 2024 (the “Effective Date”) by and between Lipocine Inc., a Delaware corporation (“Lipocine”), and Gordon Silver Limited, an Irish corporation (“GSL”). Lipocine and GSL may be referred to herein individually as a “Party”, and

Lipocine to Present at 36th Annual Roth Conference

Exhibit 99.1 Lipocine to Present at 36th Annual Roth Conference SALT LAKE CITY, March 6, 2024 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh V. Patel, President and Chief Executive Officer, will participate in a fireside chat and meet with investors at the 36th Annual Roth Conference, to take p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 6, 2024 LIPOCINE INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 6, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Exhibit 99.1 Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 ● Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK study ● On track for Q2-24 pivotal study topline results and planned Q4-24 NDA filing SALT LAKE CITY, February 6, 2024 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Ne

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 12, 2024 LIPOCINE INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 12, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 18, 2024 LIPOCINE INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 18, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Exhibit 99.1 Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada ● Lipocine to receive $11 million license fee ● Up to $259 million in development and commercial sales milestones ● Tiered royalties on net sales of licensed products up to 18% ● Commercialization of TLANDO transitions to Verity Pharma effective Feb.1 2024 ● Lipocine retains all rights

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (

Corporate Presentation

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2023 LIPOCINE INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction (IRS Employer of

Lipocine to Present at Biotech Showcase 2024 Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event

Exhibit 99.1 Lipocine to Present at Biotech Showcase 2024 Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event SALT LAKE CITY, December 19, 2023 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that it will present at the Biotech Showcase and host institutional investor and partn

Form of Subordinated Indenture

Exhibit 4.7 LIPOCINE INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Subordinated Debt Securities Table of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Sect

As filed with the Securities and Exchange Commission on November 22, 2023

As filed with the Securities and Exchange Commission on November 22, 2023 Registration No.

Form of Senior Indenture

Exhibit 4.6 LIPOCINE INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Senior Debt Securities Table of Contents Page article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Section 2.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Lipocine, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (3) Fee Rate Amount of Registration Fee Carr

e-Poster entitled “Oral LPCN 1148 Improves Sarcopenia and Hepatic Encephalopathy in Patients with Cirrhosis”

Exhibit 99.3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2023 LIPOCINE INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023 Results demonstrate improvements in sarcopenia and other clinically meaningful outcomes Patients converting from placebo to LPCN 1148 in the ongoing

Exhibit 99.1 Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023 Results demonstrate improvements in sarcopenia and other clinically meaningful outcomes Patients converting from placebo to LPCN 1148 in the ongoing open label extension also showed improvement in sarcopenia SALT LAKE CITY, November 13, 2023 — Lipocine Inc. (NASDAQ: LPCN), a biopharmac

Presentation entitled “Oral LPCN 1148 Improves Sarcopenia and Clinical Outcomes in Patients with Decompensated Cirrhosis”

Exhibit 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Quarterly Period ended September 30, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36357 LIPOCINE INC. (Exact

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

Exhibit 99.1 Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023 SALT LAKE CITY, November 8, 2023 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the third quarter and nine months ende

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 8, 2023 LIPOCINE INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 8, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023 “Late Breaking” abstract scheduled for oral presentation on November 13

Exhibit 99.1 Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023 “Late Breaking” abstract scheduled for oral presentation on November 13 SALT LAKE CITY, November 01, 2023 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that an abstract on LPCN 1148 has been selected for a late breaking ora

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 1, 2023 LIPOCINE INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 1, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

Exhibit 99.1 Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression ● Lipocine and FDA agreed on the acceptance criteria for the pivotal study which enables advancement of LPCN 1154 for postpartum depression (PPD) ● Company on track to initiate dosing in the pivotal study Q1’24 SALT LAKE CITY, October 26, 2023 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 26, 2023 LIPOCINE INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 26, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Corporate Presentation

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 23, 2023 LIPOCINE INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 23, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 2, 2023 LIPOCINE INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 2, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (

Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference

Exhibit 99.1 Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference SALT LAKE CITY, September 19, 2023 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that Dr. Mahesh Patel, President and Chief Executive Officer, will present and meet with investors at the 2023 Cantor Fitzgerald Global Heathc

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 19, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Quarterly Period ended June 30, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36357 LIPOCINE INC. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2023 LIPOCINE INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023

Exhibit 99.1 Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 SALT LAKE CITY, August 10, 2023 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced financial results for the second quarter and six months ended June 30, 2023, and provided a corporate update. Clinical Program Highlights N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 27, 2023 LIPOCINE INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 27, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis

Exhibit 99.1 LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis ● Met primary endpoint: treatment with LPCN 1148 increased L3 skeletal muscle index (L3-SMI) relative to placebo (P <0.01) ● Fewer hepatic encephalopathy (HE) events of grade >1 in the LPCN 1148 treatment arm relative to placebo (P < 0.05) ● More patients on LPCN 1148 reported symptom improvement compared to pla

LPCN 1148 A Novel Approach for the Management of Liver Cirrhosis Phase 2 Study Week 24 Topline Results

Exhibit 99.2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 26, 2023 LIPOCINE INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 26, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

Corporate Presentation

Exhibit 99.1

Presentation entitled “H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference, June 26, 2023”

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 26, 2023 LIPOCINE INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 26, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2023 LIPOCINE INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 23, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

Poster entitled “Efficacy and Safety of LPCN 1144 in Hypogonadal and Eugonadal Subjects for the Treatment of Nonalcoholic Steatohepatitis (NASH) with Fibrosis”

Exhibit 99.2

Poster entitled “A Multimodal Treatment Candidate for Sarcopenia in Men with Decompensated Cirrhosis: A Randomized, Placebo-Controlled Trial Evaluating LPCN 1148”

Exhibit 99.1

Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference

Exhibit 99.1 Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference SALT LAKE CITY, June 14, 2023 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced that Dr. Mahesh Patel, President and Chief Executive Officer, will

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 14, 2023 LIPOCINE INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 14, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 Phase 2 proof-of-concept study of LPCN 1148 in male cirrhotic patients with sarcopenia is fully enrolled with topline 24-week results expected mid-2023

Exhibit 99.1 Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 Phase 2 proof-of-concept study of LPCN 1148 in male cirrhotic patients with sarcopenia is fully enrolled with topline 24-week results expected mid-2023 SALT LAKE CITY, June 7, 2023 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 7, 2023 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 7, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 31, 2023 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 31, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2023 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 16, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

LPCN 1154 Oral Neuroactive Steroid for Depression Disorders – Topline Results PK Bridge Study Presentation

Exhibit 99.2

Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine’s Oral Candidate for Rapid Relief of Depression

Exhibit 99.1 Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine’s Oral Candidate for Rapid Relief of Depression ● Identified dosing regimen that enables reliance on a single confirmatory pivotal pharmacokinetic (PK) study to establish efficacy for postpartum depression (PPD) and support NDA submission ● LPCN 1154 treatment was well-tolerated with no h

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Quarterly Period ended March 31, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36357 LIPOCINE INC. (Exact name

Material Modification to Rights of Security Holders, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023

Exhibit 99.1 Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023 SALT LAKE CITY, May 11, 2023 – Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the first quarter ended March 31, 2023, and pr

Certificate of Amendment to the Amended and Restated Certificated of Incorporation of Lipocine Inc.

Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LIPOCINE INC. Lipocine Inc. (the “Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: FIRST: The name of this corporation is Lipocine Inc. and the date on which the Amended and Restated Certi

Corporate Presentation

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2023 LIPOCINE INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 7, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154

Exhibit 99.1 First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154 ● LPCN 1154 is an oral formulation of brexanolone in development for the rapid relief of postpartum depression (PPD) ● Topline study results expected in H1 2023 SALT LAKE CITY, April 3, 2023 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous Syste

Up to $15,700,000 Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-250072 Prospectus Supplement (To Prospectus dated November 23, 2020) Up to $15,700,000 Common Stock We previously entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) pursuant to which we may offer and sell shares of our common stock from time to time through Cant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2023 LIPOCINE INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction (IRS Employer of inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36357 LIPOCINE INC. (Exact name

Certificate of Designation of Series B Preferred Stock

Exhibit 3.2 LIPOCINE INC. CERTIFICATE OF DESIGNATION OF SERIES B PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Lipocine Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors of the Corporation (the “Board of Directors”), in accorda

Certificate of Designation of Series B Preferred Stock

Exhibit 3.6 LIPOCINE INC. CERTIFICATE OF DESIGNATION OF SERIES B PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Lipocine Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors of the Corporation (the “Board of Directors”), in accorda

Certificate of Designation of the Series B Preferred Stock of the Company, dated March 10, 2023

Exhibit 3.1 LIPOCINE INC. CERTIFICATE OF DESIGNATION OF SERIES B PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Lipocine Inc., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors of the Corporation (the “Board of Directors”), in accorda

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 07, 2023 LIPOCINE INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 07, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction (IRS Employer of inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 10, 2023 LIPOCINE INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 10, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (I

Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock

Exhibit 99.1 Lipocine Announces Pro Rata Distribution of Series B Preferred Stock to its Holders of Common Stock SALT LAKE CITY, MARCH 10, 2023 — Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred

Amendment to the Amended and Restated Bylaws of Lipocine Inc.

Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF LIPOCINE INC. The undersigned, in his capacity as the President and Chief Executive Officer of Lipocine Inc. (the “Corporation”), hereby certifies on behalf of the Corporation that the following Amendment to the Amended and Restated Bylaws of the Corporation (the “Bylaws”) was duly adopted by the Board of Directors of the Corporation on M

Lipocine Announces Financial Results for the Year Ended December 31, 2022

Exhibit 99.1 Lipocine Announces Financial Results for the Year Ended December 31, 2022 SALT LAKE CITY, March 10, 2023 – Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (“CNS”) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the year ended December 31, 2022 and provided a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 LIPOCINE INC. (Exact name of registrant as sp

8-A12G 1 form8a12g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 LIPOCINE INC. (Exact name of registrant as specified in its charter) Delaware 99-0370688 (State or other jurisdiction of incorporation or organization) (IRS Employer Identi

SUBSIDIARIES

EXHIBIT 21.1 SUBSIDIARIES Lipocine Operating Inc.

Presentation entitled “Biotech Showcase Presentation”

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 11, 2023 LIPOCINE INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 11, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction (IRS Employer of i

Corporate Presentation

EX-99.1 2 ex99-1.htm Exhibit 99.1

Lipocine to Present at Biotech Showcase Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event

Exhibit 99.1 Lipocine to Present at Biotech Showcase Company Management Will Also Host Meetings at LifeSci Partners Corporate Access Event SALT LAKE CITY, January 5, 2023 ? Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (?CNS?) disorders by leveraging its proprietary platform to develop differentiated products, today announced that its manageme

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 5, 2023 LIPOCINE INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 5, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 5, 2023 LIPOCINE INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 5, 2023 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2022 LIPOCINE INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis Top-line 24-week results from proof-of-concept study expected mid-2023

Exhibit 99.1 Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis Top-line 24-week results from proof-of-concept study expected mid-2023 SALT LAKE CITY, December 19, 2022 ? Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (?CNS?) disorders by leveraging its proprietary platform to develop differentiated products, t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 6, 2022 LIPOCINE INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 6, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Quarterly Period ended September 30, 2022 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36357 LIPOCINE INC. (Exact

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022

Exhibit 99.1 Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022 SALT LAKE CITY, November 9, 2022 /PRNewswire/ ? Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (?CNS?) disorders by leveraging its proprietary platform to develop differentiated products, today announced financial results for the third quarter and n

Poster entitled “Histologic Assessments by Pathologists and Digital Pathology Describe the Antifibrotic Effect of LPCN 1144”

Exhibit 99.3

Poster entitled “Quantitative Digital Pathology and Imaging Methods Demonstrate the Consistent Reduction of Liver Fat Burden in Patient Treated with LPCN 1144”

Exhibit 99.2

Poster entitled “Efficacy, Safety, and Tolerability of Continued LPCN 1144 Treatment in Nonalcoholic Steatohepatitis (NASH) Subjects with Fibrosis in an Open Label Extension Study”

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 4, 2022 LIPOCINE INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 4, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2022 LIPOCINE INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline

Exhibit 99.1 Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline SALT LAKE CITY, November 3 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating CNS disorders by leveraging its proprietary platform to develop differentiated products, today announced George Nomikos, M.D., Ph.D., has joined Lipocine as Chief Medical Officer and Spyros Papa

HISTOLOGIC ASSESSMENT BY PATHOLOGISTS AND DIGITAL PATHOLOGY DESCRIBE THE ANTIFIBROTIC EFFECT OF LPCN 1144

Exhibit 99.3 HISTOLOGIC ASSESSMENT BY PATHOLOGISTS AND DIGITAL PATHOLOGY DESCRIBE THE ANTIFIBROTIC EFFECT OF LPCN 1144 Li Chen1, Benjamin J Bruno2, Nachiappan Chidambaram2, Cynthia Behling3, Mathieu M Petitjean1 and Arun J. Sanyal4, (1)Pharmanest Inc, (2)Lipocine Inc., (3)Pediatrics, University of California, San Diego, (4)Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonweal

EFFICACY, SAFETY, AND TOLERABILITY OF CONTINUED LPCN 1144 TREATMENT IN NONALCOHOLIC STEATOHEPATITIS (NASH) SUBJECTS WITH FIBROSIS IN AN OPEN LABEL EXTENSION STUDY (OLE)

Exhibit 99.1 EFFICACY, SAFETY, AND TOLERABILITY OF CONTINUED LPCN 1144 TREATMENT IN NONALCOHOLIC STEATOHEPATITIS (NASH) SUBJECTS WITH FIBROSIS IN AN OPEN LABEL EXTENSION STUDY (OLE) Benjamin J Bruno1, Kongnara Papangkorn1, Anthony DelConte1,2, Kilyoung Kim1, Nachiappan Chidambaram1, Mahesh V Patel1, Somaya Albhaisi3 and Arun J. Sanyal3, (1)Lipocine Inc., (2)Department of Pharmaceutical/Healthcare

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 27, 2022 LIPOCINE INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 27, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

QUANTITATIVE DIGITAL PATHOLOGY AND IMAGING METHODS DEMONSTRATE THE CONSISTENT REDUCTION OF LIVER FAT BURDEN IN PATIENTS TREATED WITH LPCN 1144

Exhibit 99.2 QUANTITATIVE DIGITAL PATHOLOGY AND IMAGING METHODS DEMONSTRATE THE CONSISTENT REDUCTION OF LIVER FAT BURDEN IN PATIENTS TREATED WITH LPCN 1144 Li Chen1, Benjamin J Bruno2, Nachiappan Chidambaram2, Cynthia Behling3, Mathieu M Petitjean1 and Arun J. Sanyal4, (1)Pharmanest Inc, (2)Lipocine Inc., (3)Pediatrics, University of California, San Diego, (4)Division of Gastroenterology, Hepatolo

Exhibit 99.1

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 17, 2022 LIPOCINE INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 17, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation)

Corporate Presentation

Exhibit 99.1

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 28, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 26, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation

Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders Company to apply its proprietary Lip’ral oral drug delivery technology to advance a pipeline of differentiated products for Central Nervous System (CNS) disorders In

EX-99.1 3 ex99-1.htm Exhibit 99.1 Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders Company to apply its proprietary Lip’ral oral drug delivery technology to advance a pipeline of differentiated products for Central Nervous System (CNS) disorders Initial focus on oral delivery of neuroactive steroids; important near-term clinical milestone for lead candidate LPCN

Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)

Exhibit 99.1 Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) ? FDA agrees with Lipocine establishing LPCN 1154 pathway to efficacy through a pharmacokinetic (PK) bridge to an approved IV infusion brexanolone ? Lipocine has demonstrated that the brexanolone exposure of LPCN 1154 is similar to the levels observed in third trimester pregnant women sa

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 15, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For Quarterly Period ended June 30, 2022 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to . Commission File Number: 001-36357 LIPOCINE INC. (Exact name

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022

Exhibit 99.1 Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022 SALT LAKE CITY, August 8, 2022 ? Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system (?CNS?) disorders, today announced financial results for the second quarter ended June 30, 2022 and provided a corporate update.

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (I

FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment Phase 2 Photosensitive Epilepsy Study Planned for 2H 2022

Exhibit 99.1 FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment Phase 2 Photosensitive Epilepsy Study Planned for 2H 2022 SALT LAKE CITY, July 11, 2022 /PRNewswire/ ? Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products to treat metabolic and central nervous system (?CNS?) disorders with high unmet medical needs, announced today that the U.S. Food

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 11, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 24, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 28, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Lipocine Inc.

Exhibit 3.4 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LIPOCINE INC. Lipocine Inc. (the ?Company?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?DGCL?), does hereby certify that: FIRST: The name of this corporation is Lipocine Inc. and the date on which the Amended and Restated Certifica

LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS

Exhibit 99.1 LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS SALT LAKE CITY, UT, June 14, 2022 - Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the United States Patent and Trademark Office (USPTO) has granted US patent 11,337,987 for ?Compositions and Methods for Treating Central Nervous System (CNS)

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 14, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 10, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IR

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 8, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 6, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

LIPOCINE ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE

Exhibit 99.1 LIPOCINE ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE SALT LAKE CITY, June 6, 2022 ? Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, presented ?LPCN 2101: An Endogenous Neuroactive Steroid for Epilepsy? today at the 2022 Epilepsy Foundation Pipeline Conference. The

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 6, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Presentation entitled “LPCN 2101: An Endogenous Neuroactive Steroid for Epilepsy”

Exhibit 99.1

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2022 LIPOCINE INC. (Exact name of registrant as specified in its charter) Commission File No. 001-36357 Delaware 99-0370688 (State or other jurisdiction of incorporation) (IRS

Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results

Exhibit 99.1 Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results ? LPCN 1144 was well tolerated over 72-week exposure with no observed safety signals ? Liver injury markers were reduced and maintained with extended LPCN 1144 treatment ? Observed liver histology improvements support further development SALT LAKE CITY, May 12, 2022 /PRNewswire/ ? Lipocine Inc. (NASDAQ: LPCN